🇯🇵·1d agoIndustryTier 1 · Company source
GYM329 (emugrobart) の肥満症開発中止、ライセンス返還およびSMA開発再開に関するお知らせ
Publisher
C
Chugai Pharmaceutical News
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the publisher's original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical News
- Region
- Japan
- Scope
- Industry
- Published
- September 28, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Evidence: Tier 1 · Company source
Related coverage
More related coverage
Certara/19h ago
Certara Transitions Chemaxon Support to Certara Service Desk
Interpharma Switzerland/19h ago
Warum der Blick auf Medikamentenkosten zu kurz greift
AbbVie News/21h ago
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
Merck & Co. (MSD) News/23h ago